Abstract：Objective: To study the effects of gefitinib targeted therapy on epidermal growth factor and immune function in patients with late stage EGFR gene mutation non-small cell lung cancer (NSCLC). Methods: 120 patients with late stage EGFR gene mutation NSCLC who were admitted to the hospital from January 2016 to August 2017 were selected and divided into control group and observation group according to simple random grouping method. Control group was given conventional chemotherapy regimen, and observation group was given gefitinib on the basis of control group, and they were treated for 4 cycles with a cycle of 28d. The efficacy, incidence rate of toxic and side effects of III and IV chemotherapy were counted in the two groups. The levels of T lymphocytes, immunoglobulins, serum and pleural effusion EGFR were detected. Results: The disease control rate and effective rate of treatment in observation group were higher than those in control group (P<0.05). The CD3+, CD4+ and CD4+/CD8+ levels in observation group after treatment were higher than those in control group while the CD8+ level was lower than that in control group (P<0.05). The immunoglobulins indexes in observation group after treatment were higher than those in control group (P<0.05). The levels of epidermal growth factor receptor (EGFR) in serum and pleural effusion after treatment in observation group were lower than those in control group (P<0.05). Conclusions: Gefitinib targeted therapy can significantly reduce EGFR level and improve immune function in the treatment of late stage EGFR gene mutation NSCLC.
[1] Thomas A,Liu S V,Subramaniam D S,et al.Refining the treatment of NSCLC according to histological and molecular subtypes[J].Nature Reviews Clinical Oncology,2015,12(9):511. [2] Gainor J F,Tan D S W,De Pas T,et al.Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib[J].Clinical Cancer Research,2015,21(12):2745~2752. [3] Russo A,Franchina T,Ricciardi G R R,et al.A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer(NSCLC):Old successes and future perspectives[J].Oncotarget,2015,6(29):26814~26825. [4] Chuang J C,Neal J W,Niu X M,et al.Adjuvant therapy for EGFR mutant and ALK positive NSCLC:current data and future prospects[J].Lung Cancer,2015,90(1):1~7. [5] 李雅,常红莉,王哲,等.吉非替尼靶向治疗中晚期非小细胞肺癌40例[J].现代肿瘤医学,2015,23(20):2959~2961. [6] 李琦,罗天友,吕发金,等.能谱CT定量分析在确定非小细胞肺癌病理类型中的价值[J].中华放射学杂志,2017,51(4):257~261. [7] 张娜,钟国民.多层螺旋CT与X线检查在肺癌临床诊断中的应用[J].医学影像学杂志,2016,26(1):133~135. [8] 宋勇,杨雯.2014年晚期非小细胞肺癌内科治疗进展[J].解放军医学杂志,2015,40(1):10~15. [9] 王志海,彭宗玉,杜国威,等.EGFR突变型转移性非小细胞肺癌的靶向治疗疗效及安全性[J].癌症进展,2017,15(7):771~773. [10] 张立文.吉非替尼对非小细胞肺癌患者免疫功能的影响[J].中国药物与临床,2018,18(9):1554~1556.
2019, Vol. 25 
冀公网安备13080202000677号